San Diego startup AltheaDx, which developed a molecular test designed to guide therapy for depression and anxiety based on a patient’s genetics, is being acquired for $65 million in stock and cash. Castle Biosciences of Houston said Monday that it reached a deal to buy the roughly 40 employee company to advance its lead mental health diagnostic test, which is branded IDgenetix. The precision medicine test helps clinicians pinpoint the right drugs for battling depression based on how it interacts with a patient’s genes. The test also helps uncover how a drug might interact with other medication…
